Cancer therapeutics - 1 News by Leibniz-Institut für Molekulare Pharmakologie from Germany

Cancer therapeutics - 1 News by Leibniz-Institut für Molekulare Pharmakologie from Germany

image description

Novel cancer therapeutic with components from basic research enters clinical phase

"I am excited by the progress the Tubulis team has made over the last few years toward this major milestone"

24-Jun-2024 - Groundbreaking innovations by researchers at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) provided the basis for the development of an antibody-drug conjugate (ADC) by the company Tubulis, which is now being used in a Phase I/IIa trial in tumour patients. Thanks to an ...

cancer therapeutics antibody conjugates antibody-drug conjugates
Haven't found the right news yet?

The bionity.com news search

Start your targeted search now with a wide range of filter options. Our database includes an archive of 26,967 life science news from business and science, which you can search by topic and organization, filtered by time and geography.

Start news search now